• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

The Drugs for Neglected Diseases initiative unveils its vision for global health R&D for the next decade

Developing 25 medicines in 25 years to help address the many injustices and inequalities facing our world today

Home > Press releases

The Drugs for Neglected Diseases initiative unveils its vision for global health R&D for the next decade

Developing 25 medicines in 25 years to help address the many injustices and inequalities facing our world today

Healthcare workers in hospital setting with documents
Geneva, Switzerland — 30 Mar 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • Deutsch
    • English
    • Español
    • Français
    • Português

The non-profit research and development (R&D) organization the Drugs for Neglected Diseases initiative (DNDi) is launching a new drug discovery, development, and access agenda that doubles down on neglected patient needs, prepares for future pandemics and climate-sensitive diseases, and prioritizes the development of appropriate treatments for women and children.  

As part of its Strategic Plan 2021-2028,the organization aims to deliver 15 to 18 new treatments, for a total of 25 new treatments in its first 25 years.

Since its creation in 2003, DNDi has delivered eight treatments for neglected patients, including most recently fexinidazole, the first all-oral treatment for sleeping sickness and DNDi’s first new chemical entity (NCE). DNDi aims to deliver 10 to 12 treatments by 2024 thanks to its current, mature portfolio, and 5 to 7 treatments from earlier-stage NCEs and portfolio expansion to address new areas of unmet medical need.

The Plan was developed following a year-long consultation exercise with DNDi’s founding partners, leading global health research and industry experts, and dozens of DNDi’s more than 200 partner organizations around the world.

‘Our Strategic Plan comes at a moment when the COVID-19 crisis is shining a glaring light on the inequalities of our global biomedical system, which has for too long ignored the R&D needs of neglected populations living in low- and middle-income counties,’ said Dr Bernard Pécoul, Executive Director of DNDi. ‘Our vision for global health R&D for the next decade is to contribute to a more equitable system for innovation and access, where we not only address clear treatment gaps for infectious diseases, but also help to drive wider systemic changes needed to ensure access to the fruits of scientific progress for all people in need.’

DNDi will prioritize the needs of patients affected by neglected tropical diseases and viral diseases that exact a disproportionate toll on already vulnerable and neglected communities. The organization will join with its founding partners, science leaders, and research allies in LMICs as equal partners to define R&D priorities, strengthen South-South and cross-regional research collaborations. We will partner for impact by expanding industry networks, notably in low- and middle-income countries. And DNDi will continue to push for open, transparent, and collaborative research – speaking out for the policies and political will needed to re-orient the global biomedical R&D system to focus on patients’ needs, not profits.

DNDi’s Strategic Plan was launched today at a webinar featuring Dr Marie-Paule Kieny, Director of Research, INSERM and DNDi Board Chair, Dr Bernhards Ogutu, Chief Research Officer, KEMRI and DNDi Board Member, Dr Jeremy Farrar, Director, Wellcome, Dr Soumya Swaminathan, Chief Scientist, World Health Organization, and Dr Bernard Pécoul Executive Director of DNDi.

DNDi will seek the support of governments, other funding institutions, and private philanthropy to raise EUR 612 million for the 2021-2028 period, including EUR 136 million already secured.

Strategic Plan 2021-2028 coverpage
READ our strategic plan
Strategic Plan 2021-2028 at a glance coverpage
READ our plan summary

About DNDi

A not-for-profit research and development organization, DNDi  works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating a clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi  has delivered eight new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org 

Media contact

Frédéric Ojardias
fojardias@dndi.org 
+41 79 431 62 16 

Photo credit: Lameck Ododo/DNDi

Read, watch, share

Loading...
Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Press releases
8 Apr 2022

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY